Latent Tuberculosis Clinical Trial
Official title:
Improving Rhode Island's Tuberculosis Preventive Services in Primary Care: A Mixed-Methods Evaluation of an Innovative Telementoring Model
Verified date | March 2022 |
Source | Kent Hospital, Rhode Island |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study explores primary care team members' knowledge, attitudinal, and skill gaps related to LTBI testing and treatment. The gaps identified will inform the design of a survey and telementoring educational program (TB infection ECHO course). The EMR data query will further explore the reach of the ECHO model. The hypothesis for this study is that the TB infection ECHO course will be feasible, will have a significant impact on primary care provider participants' learning and performance related to LTBI testing and treatment in their primary care practices, and will increase the number of LTBI tests and treatment prescribed in primary care.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | July 31, 2022 |
Est. primary completion date | March 24, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - > 18 years of age - Primary care team members in Rhode Island including doctors, nurses, nurse practitioners, physician assistants, or other healthcare providers who are involved in primary care. Exclusion Criteria: - < 18 years of age - Primary care team members who do not primarily work in Rhode Island |
Country | Name | City | State |
---|---|---|---|
United States | Brown Family Medicine Department | Pawtucket | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Kent Hospital, Rhode Island | National Institute of General Medical Sciences (NIGMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility: Participant Attendance | Proportion of registered participants attending each ECHO session | Six-month ECHO course | |
Primary | Feasibility: Participant Retention | Proportion of registered participants attending one of the last two ECHO sessions | Six-month ECHO course | |
Primary | Impact: Procedural knowledge | Change in participants' confidence in knowing TB infection testing and treatment procedures based on a likert scale rating (1=not at all confident and 5=extremely confident) included in the pre- and post- structured surveys administered before and after the ECHO intervention. | Six-month ECHO course | |
Primary | Impact: Self- reported LTBI screening | Change in participants' self-reported estimates of patients screened for TB infection. Participants will estimate their screening on a 5 item scale with 0 patients being the lowest and >50 patients being the highest. Change in scores will be calculated between the pre- and post- structured survey responses administered before and after the ECHO intervention. | Six-month ECHO course | |
Primary | Impact: Self- reported LTBI treatment | Change in participants' self-reported estimates of patients treated for TB infection. Participants will estimate their TB treatment on a 5 item scale with 0 patients being the lowest and >50 patients being the highest. Change in scores will be calculated between the pre- and post- structured survey responses administered before and after the ECHO intervention. | Six-month ECHO course | |
Primary | Reach: LTBI testing | Proportion(# of TB tests/# of visits) of patients tested for LTBI in a health center population before, during and after ECHO implementation to assess providers' behavior change. This data will be obtained from an electronic medical record data query | Three-months prior, ECHO course, three- months post | |
Primary | Reach: LTBI treatment | Patient level LTBI treatment before, during and after ECHO implementation to assess providers' behavior change. Proportion(# of TB treatment initiated/# of patients diagnosed with LTBI) of patients treated for LTBI in a health center population before, during and after ECHO implementation to assess providers' behavior change. This data will be obtained from an electronic medical record data query. | Three-months prior, ECHO course, three- months post | |
Secondary | Feasibility: Case Submission | Proportion of cases submitted on time during the ECHO course | Six-month ECHO course | |
Secondary | Feasibility: ECHO session timing | Proportion of participants' who agree that session timing was convenient. This will be collected monthly from post-session surveys via a likert scale (1=strongly disagree and 5=strongly agree) | Six-month ECHO course | |
Secondary | Feasibility: Connectivity | Proportion of participants' who agree that connectivity was adequate during the ECHO session. This will be collected monthly from post-session surveys via a likert scale (1=strongly disagree and 5=strongly agree) | Six-month ECHO course | |
Secondary | Feasibility: Videoconferencing Equipment | Proportion of participants' who agree that videoconferencing equipment was adequate during the ECHO session. This will be collected monthly from post-session surveys via a likert scale (1=strongly disagree and 5=strongly agree) | Six-month ECHO course | |
Secondary | Feasibility: Content expert facilitation | Proportion of participants' who agree that the quality of content expert facilitation was adequate during the ECHO session. This will be collected monthly from post-session surveys via a likert scale (1=strongly disagree and 5=strongly agree) | Six-month ECHO course | |
Secondary | Feasibility: Communication with ECHO hub | Proportion of participants' who agree that the communication with the ECHO hub team was adequate during the ECHO session. This will be collected monthly from post-session surveys via a likert scale (1=strongly disagree and 5=strongly agree) | Six-month ECHO course |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
Not yet recruiting |
NCT04428294 -
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
|
Phase 4 | |
Completed |
NCT02276755 -
Vitamin D Supplementation in TB Prevention
|
Phase 3 | |
Withdrawn |
NCT03498534 -
Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
|
Phase 4 | |
Active, not recruiting |
NCT03988933 -
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
|
Phase 2 | |
Recruiting |
NCT06022146 -
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
|
Phase 3 | |
Recruiting |
NCT03730181 -
Tuberculosis Clinical Trials Consortium Study 35
|
Phase 1/Phase 2 | |
Completed |
NCT01967134 -
Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
|
Phase 1 | |
Completed |
NCT00257907 -
Immune Response to Mycobacterium Tuberculosis Infection
|
||
Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
Active, not recruiting |
NCT04557176 -
TB Screening Improves Preventive Therapy Uptake
|
N/A | |
Completed |
NCT02119130 -
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
|
N/A | |
Not yet recruiting |
NCT06281834 -
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
|
Phase 1 | |
Not yet recruiting |
NCT02512484 -
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
|
N/A | |
Completed |
NCT00763295 -
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
|
N/A | |
Completed |
NCT01850043 -
The Epidemiology of TST Change in Korea
|
N/A | |
Completed |
NCT02073669 -
Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults
|
N/A | |
Completed |
NCT02090374 -
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
|
N/A | |
Completed |
NCT02880982 -
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
|
Phase 3 | |
Withdrawn |
NCT03783728 -
Video Based Directly Observed Therapy for Latent TB
|